Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SpaceXs rally is drawing attention after Morgan Stanley reiterated a bullish view ahead of Starship Flight 15, with traders also pointing to breakout momentum and possible short-covering. Bulls are celebrating the move, while skeptics question the valuation and flag upcoming share unlocks.

Novavaxs sharp rally is being linked by traders to reports of a suspected plague exposure in Russia, which has revived pandemic-preparedness speculation around vaccine stocks. The community also points to Novavaxs partner vaccine business and heavy short interest, debating whether the move reflects fundamentals, outbreak-driven FOMO, or a potential short squeeze.

Shareholder approval of Evernorths merger with Armada, paving the way for its Nasdaq debut as an XRP treasury company, is driving attention. Traders are treating XRPN as a speculative, low-float XRP play, while skeptics argue its sharp run-up may outstrip the value of its underlying holdings and warn of a pullback; warrants and potential dilution are also fueling debate.

Amazons reported plan to move Nvidia AI chips into an investor-backed vehicle and lease them back has prompted debate over whether it is balance-sheet management or a warning sign about AI spending. That discussion sits alongside widespread frustration with AMZNs choppy underperformance, while bulls point to AWS and AI demand as reasons for optimism.

Capricors 24-month HOPE-3 open-label extension data on deramiocels effect on upper-limb decline in Duchenne muscular dystrophy has renewed attention ahead of the FDA decision. Despite optimism about the data, the share-price drop has fueled debate over whether it can overcome prior statistical concerns, with some traders highlighting an analysts expectation of a complete response letter and others viewing the data as supportive of approval.

GRRR is under pressure as traders focus on uncertainty around financing its AI data-center projects, with fears of further dilution and doubts that announced contracts will translate into revenue and cash flow. Bulls point to Yotta deployment progress and the companys contract backlog, but many are waiting for clearer financing details and proof of execution.

AAOI is drawing attention as traders react to the reported completion of its at-the-market share-sale program, which they hope will ease dilution and selling pressure. Bulls also point to AI data-center optics demand, while skeptics remain concerned about further dilution and the stocks volatility.

Vaxcytes VAX-31 met the primary endpoints in its pivotal Phase 3 OPUS-1 trial in adults, fueling a sharp rally and optimism about its potential to compete with established pneumococcal vaccines. Traders are also debating dilution risk from the proposed stock and convertible-note offerings, alongside profit-taking and short-term volatility.

MercadoLibre is rallying alongside Brazilian and Latin American stocks after traders linked the move to Flvio Bolsonaros strong first-round election showing, viewing the result as a potential boost to regional equities. The move is widely characterized as political and macro-driven rather than company-specific, though some traders question whether the election news alone justifies the jump.

Chipotle is drawing attention after a sharp selloff, with traders largely citing weakness across restaurant and consumer-discretionary stocks rather than a clear company-specific catalyst. The drop has prompted frustration and dip-buying, while some traders point to concerns about restaurant traffic, value, and customer experience; options activity is also elevated.